ACC Highlights 2024

Program Access
Overview & Objectives
Credit Eligibility
Funding Support

View Agenda

View Session
Duration:	90 Minutes
Featuring:	Drs Milan Gupta and Narendra Singh
Credits:	N/A
Details:	Navigate using individual content links

Date

April 15, 2024

Time

90 Minutes

Credits

Non-certified credits

Details

Navigate using individual content links

View Agenda

Description

This program covered the key clinical trial findings and their implications from ACC 2024. This program is intended for cardiovascular specialists and primary care physicians.

Learning Objectives

Following participation in this program, participants will be able to:

Review trials and data presented at ACC 2024
Examine where the data presented may impact clinical practice guidelines
Apply the latest evidence-based strategies in clinical practice

Discussion Topics

EMPACT-MI – Does empagliflozin improve outcomes after acute MI?
VICTORION-INITIATE – Comparing inclisiran first to
usual care in patients with ASCVD
STEP-HFpEF DM – What is the role of semaglutide for patients with diabetes and HFpEF?
TACT2 – Does chelation reduce events in diabetic
post-MI patients?
REDUCE-AMI – Do beta-blockers impact outcome
following acute MI with preserved EF?

Faculty

Milan Gupta: MD, FRCPC, FCCS, CPC(HC)
Narendra Singh: MD, FRCPC, FCCS, FACC, FAHA

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.

Program Chapter

Presenter

This program was developed by CCRN and has received unrestricted educational grant funding.

View Sponsorship Details